Similar Survival in Patients Following Heart Transplantation Receiving Induction Therapy Using Daclizumab vs. Basiliximab

BACKGROUND: Induction therapy with interleukin-2 receptor antagonists has been established as an effective immunosuppressive strategy in the management of heart transplant (HTx) recipients. We compared outcomes following HTx in patients receiving basiliximab, daclizumab, or no induction therapy. MET...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Circ J
Main Authors: Martin, Spencer T., Kato, Tomoko S., Farr, Maryjane, McKeen, Jaclyn T., Cheema, Faisal, Ji, Mengxi, Ross, Alexandra, Yerebakan, Halit, Naka, Yoshifumi, Takayama, Hiroo, Restaino, Susan, Mancini, Donna, Schulze, P. Christian
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4967552/
https://ncbi.nlm.nih.gov/pubmed/25501951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1253/circj.CJ-14-0718
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados